scPharmaceuticals Inc. (NASDAQ:SCPH) Position Increased by BNP Paribas Financial Markets

BNP Paribas Financial Markets increased its stake in scPharmaceuticals Inc. (NASDAQ:SCPH - Free Report) by 1,393.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 85,900 shares of the company's stock after acquiring an additional 80,147 shares during the period. BNP Paribas Financial Markets owned approximately 0.17% of scPharmaceuticals worth $304,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Corebridge Financial Inc. raised its holdings in scPharmaceuticals by 29.0% in the fourth quarter. Corebridge Financial Inc. now owns 19,586 shares of the company's stock valued at $69,000 after buying an additional 4,406 shares during the period. Balanced Rock Investment Advisors LLC raised its stake in shares of scPharmaceuticals by 8.7% during the fourth quarter. Balanced Rock Investment Advisors LLC now owns 70,362 shares of the company's stock valued at $249,000 after purchasing an additional 5,612 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of scPharmaceuticals by 31.6% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 23,471 shares of the company's stock valued at $84,000 after purchasing an additional 5,633 shares during the period. Bank of New York Mellon Corp raised its stake in shares of scPharmaceuticals by 8.8% during the fourth quarter. Bank of New York Mellon Corp now owns 75,174 shares of the company's stock valued at $266,000 after purchasing an additional 6,051 shares during the period. Finally, Invesco Ltd. raised its stake in shares of scPharmaceuticals by 28.2% during the fourth quarter. Invesco Ltd. now owns 27,614 shares of the company's stock valued at $98,000 after purchasing an additional 6,073 shares during the period. Hedge funds and other institutional investors own 89.52% of the company's stock.

scPharmaceuticals Stock Down 0.3%

Shares of NASDAQ:SCPH traded down $0.01 during midday trading on Friday, reaching $3.54. The company had a trading volume of 288,816 shares, compared to its average volume of 368,843. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The stock's fifty day moving average price is $2.68 and its 200-day moving average price is $3.12. The stock has a market capitalization of $186.88 million, a P/E ratio of -1.86 and a beta of 0.17. scPharmaceuticals Inc. has a one year low of $1.94 and a one year high of $5.65.

scPharmaceuticals (NASDAQ:SCPH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.06). The company had revenue of $11.75 million during the quarter, compared to the consensus estimate of $11.63 million. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. Equities research analysts expect that scPharmaceuticals Inc. will post -1.53 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on SCPH shares. Maxim Group dropped their price objective on shares of scPharmaceuticals from $20.00 to $12.00 and set a "buy" rating on the stock in a research note on Thursday, March 20th. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of scPharmaceuticals in a research note on Thursday, March 20th.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.